Complete remission of an early-stage laryngeal cancer under combined pembrolizumab and chemotherapy treatment of a synchronous lung adenocarcinoma

BACKGROUND: Anti-PD1-Checkpoint inhibition (CI) is an established treatment of recurrent and/or metastatic head and neck cancer. A potential benefit from CI in early-stage disease that is usually treated by radiation or surgery has not been investigated so far and is currently not addressed in clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Linxweiler, Maximilian, Kühn, Jan Philipp, Neubert, Christian, Khreish, Fadi, Balensiefer, Benedikt, Wagner, Mathias, Schick, Bernhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109389/
https://www.ncbi.nlm.nih.gov/pubmed/35578359
http://dx.doi.org/10.1186/s40463-022-00572-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109389/
https://www.ncbi.nlm.nih.gov/pubmed/35578359
http://dx.doi.org/10.1186/s40463-022-00572-y

Ejemplares similares